# Promoting Brain Resilience to Alzheimer's Neuropathology

> **NIH NIH R01** · UNIVERSITY OF TEXAS MED BR GALVESTON · 2020 · $806,795

## Abstract

PROJECT SUMMARY/ABSTRACT
Finding a resolving cure for Alzheimer’s Disease (AD), is an urgent critical need. There is ample consensus that
successful treatments should target early pathological events in AD. Among these, synaptic dysfunction induced
by oligomers of both A and tau is recognized as one of the earliest key driving events in AD and thus an
attractive treatment target, but an effective strategy is still missing. Our long-term goal is to help develop
therapeutically useful approaches to increase synaptic resilience to A and tau oligomers for the clinical
treatment of AD patients. With this goal in mind, we recently reported that exosomes specifically released by
hippocampal neural stem cells (NSC-exo) render CNS synapses resilient to the disruptive impact of A oligomers
via selected micro RNA (miRNA) cargoes, a mechanism likely at play in the human brain as suggested by reports
of aged individuals with high numbers of NSC and synapses resilient to A oligomers who remain cognitively
intact despite the CNS presence of extensive AD neuropathology. Whether such mechanism of resilience is also
effective against synaptic disruption brought about by tau oligomers- a recognized major player in the onset and
clinical progression of AD- remain to be established. Thus, the overall objective in this application, is to evaluate
the link between NSC (and their released exosomes) and increased synaptic resilience to the toxic actions of
tau oligomers as a function of aging, the strongest AD risk factor. Based of rigorous previous literature reports
and compelling preliminary results, our central hypothesis is that NSC-exo, via delivering unique miRNA cargoes,
render synapses resistant to toxic tau oligomers and that such protective mechanism fails during aging owing to
the well-documented age-related loss of NSC, leaving the aged brain more vulnerable to the AD toxic amyloids
(and therefore more at risk of developing clinically manifest AD). The rationale for this project is that a
determination of the preclinical therapeutic efficacy and associated mechanisms of NSC-exo (and their miRNA
cargoes) as a function of aging is likely to offer a strong scientific framework whereby a new strategy centered
on promoting synaptic resilience to AD pathological oligomers could be developed. To obtain the overall objective,
we will pursue three specific aims that will evaluate the efficacy of NSC-exo in promoting synaptic resilience to
Tau oligomers (Aim 1), determine the invoved miRNA cargoes and their impact on key synaptic proteins (Aim
2) and evaluate the impact of aging on such protective mechanisms as a function of decreasing numbers of
resident NSC and their released exosomes (Aim 3). At the completion of the proposed studies, it is our
expectation that we will have documented a previously unappreciated phenomenon of synaptic resistance to
toxic oligomers mediated by NSC-exo and their miRNA cargo that fails during aging. This discovery will illustrate
t...

## Key facts

- **NIH application ID:** 10071759
- **Project number:** 1R01AG069433-01
- **Recipient organization:** UNIVERSITY OF TEXAS MED BR GALVESTON
- **Principal Investigator:** Maria-Adelaide Micci
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $806,795
- **Award type:** 1
- **Project period:** 2020-08-01 → 2025-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10071759

## Citation

> US National Institutes of Health, RePORTER application 10071759, Promoting Brain Resilience to Alzheimer's Neuropathology (1R01AG069433-01). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10071759. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*